

## Pediatric Cancer Conference - 12/4/2024 Patient Review for process improvement and care plan

### **Accreditation**

Memorial Healthcare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### **Credit**

Memorial Healthcare System designates this live activity for a maximum of **1.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Disclosure**

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), Memorial Healthcare System resolves all conflicts of interest to ensure CME activities are free of commercial bias.

### **Contact information for the activity:**

**Iftikhar Hanif, Karen Maya, Heather DeGance, Sintia Lopez,**  
**IHANIF@MHS.NET,**  
**KaMaya@mhs.net,**  
**HDeGance@mhs.net.**

**PRESENTER:** Carmen S Ballestas, MD; Brian E Cauff, MD; Iftikhar Hanif, MD; Deborah L Kramer, MD; Kerice Pinkney, MD; Anne Marie Schaefer, MD  
**JDCH Center for Cancer and Blo**

**DATE:** December 4, 2024

**TIME:** 12:30 PM

**PLACE:** Joe Dimaggio Children's Hospital

**TARGET AUDIENCE:** Pediatrics, Adolescent Medicine, Child Abuse Pediatrics, Developmental-Behavioral Pediatrics, Neonatal-Perinatal Medicine, Pediatric Cardiology, Pediatric Critical Care Medicine, Pediatric Endocrinology, Pediatric Gastroenterology, Pediatric Hematology-Oncology, Pediatric Infectious Diseases, Pediatric Nephrology, Pediatric Pulmonology, Pediatric Rheumatology, Pediatric Sports Medicine, Pediatric Transplant Hepatology, Pediatric Orthopedic Surgery

### **LEARNING OBJECTIVES:**

At the conclusion of this activity participants will be able to:

- 1 Identification of newer molecular findings in different pediatric tumors
- 2 Risk assesment of patients in different disease with the hep of radiology, example use of PET for classification of Hodgkin's disease or use of MIBG scan in cases of neuroblastoma
- 3 Discussion of ongoing and newer targeted therapies and their impact, as data has started to mature.

### **DISCLOSURES:**

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Iftikhar Hanif, MD	Activity Administrator, Faculty	Nothing to disclose - 03/15/2024
Deborah L Kramer, MD	Faculty	Nothing to disclose - 05/29/2024
Carmen S Ballestas, MD	Faculty	Nothing to disclose - 03/14/2024
Anne Marie Schaefer, MD	Faculty	Nothing to disclose - 03/14/2024